Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mu Ji Fang (MJF) is a Traditional Chinese Medicine (TCM) formulation, primarily administered as granules, that has been used clinically in China for over 30 years to treat hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). The formula contains a complex mixture of active ingredients, including alkaloids, flavonoids, and polysaccharides. Research indicates that MJF exerts anti-tumor effects by inducing apoptosis in cancer cells and suppressing immune escape mechanisms. Its molecular mechanism involves the inhibition of the Transforming Growth Factor-beta 1 (TGF-β1)/Smad signaling pathway, which is a key driver of fibrosis and tumor progression in the liver. MJF is often utilized as a complementary or primary therapy in regional Chinese clinical settings for chronic liver diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mu Ji Fang.